SIREN : 353298656
CEVA BIOVAC is a French company founded 36 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in BEAUCOUZE (49070), this company of category ETI shows in 2024 a revenue of 15.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15 277 269 € | 12 944 523 € | 10 895 072 € | 10 516 004 € | 10 174 024 € | 9 582 484 € | 9 347 122 € | 8 549 899 € | 7 662 171 € | 7 523 126 € |
| Net income | 491 823 € | -423 271 € | -1 050 306 € | 333 807 € | 685 640 € | 622 271 € | 1 409 241 € | 1 334 212 € | 933 962 € | 1 403 973 € |
| EBITDA | 1 851 526 € | 759 381 € | -16 868 € | 942 042 € | 1 223 743 € | 1 066 002 € | 1 719 177 € | 2 131 771 € | 1 912 046 € | 2 028 704 € |
| Net margin | 3.2% | -3.3% | -9.6% | 3.2% | 6.7% | 6.5% | 15.1% | 15.6% | 12.2% | 18.7% |
In 2024, CEVA BIOVAC achieves revenue of 15.3 M€. Over the period 2015-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +8.2%. Vs 2023, growth of +18% (12.9 M€ -> 15.3 M€). After deducting consumption (3.2 M€), gross margin stands at 12.1 M€, i.e. a rate of 79%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.9 M€, representing 12.1% of revenue. Positive scissor effect: EBITDA margin improves by +6.3 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 492 k€, i.e. 3.2% of revenue. This profit can be retained or distributed to shareholders.
15 277 269 €
12 119 194 €
1 851 526 €
600 250 €
491 823 €
12.1%
The debt ratio (= Financial debt / Equity x 100) stands at 207%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 22%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.6 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 11.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
207.241%
21.701%
11.129%
4.64
57.5%
In 2024, the debt ratio of CEVA BIOVAC (207.24) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of CEVA BIOVAC (21.7%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
In 2024, the repayment capacity of CEVA BIOVAC (4.64) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 127.18. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 8.2x. Operating income very largely covers interest expenses: high safety margin.
127.183
8.219
In 2024, the liquidity ratio of CEVA BIOVAC (127.18) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of CEVA BIOVAC (8.2x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 66 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 67 days. Favorable situation: supplier credit is longer than customer credit by 1 days. Inventory turnover is 44 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 65 days of revenue, i.e. 2.7 M€ to permanently finance. Over 2015-2024, WCR increased by +101%, requiring additional financing.
2 746 089 €
66 j
67 j
44 j
65 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 98 128€ to 301 607€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare CEVA BIOVAC with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of CEVA BIOVAC in 2024 is 15.3 M€.
Yes, CEVA BIOVAC generated a net profit of 492 k€ in 2024.
The headquarters of CEVA BIOVAC is located in BEAUCOUZE (49070), in the department Maine-et-Loire.
The tax return of CEVA BIOVAC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
CEVA BIOVAC operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.